Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inbakicept is a human IL-15 superagonist with immunostimulatory properties with promising anti-cancer treatment and it is also being investigated as an HIV treatment. Inbakicept is a soluble complex consisting of two protein subunits of a human interleukin (IL)-15 variant (nogapendekin alfa) bound with high affinity to a dimeric human IL-15 receptor ¦Á (IL-15 R¦Á) sushi domain/human IgG1 Fc fusion protein. This fusion protein has been designed to simulate the normal mechanism of action of IL-15 where IL-15 and IL-15 R¦Á are coordinately expressed by antigen-presenting cells (monocytes and dendritic cells) and presented in trans to neighboring NK cells or CD8 + T cells expressing the CD122/CD132 receptor complex.
| Products Name (INN Index) | Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) |
|---|---|
| INN Name | inbakicept |
| Target | IL15 |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL- 15RA)]2 – IGHG1 Fc (Fragment constant) |
| VD LC | Fusion – [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL- 15RA)]2 – IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Altor?BioScience (FL USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL15 |
| Package |
